Oncotelic Therapeutics' IV Sapu003 Shows 67-Fold Reduction in Gastrointestinal Drug Accumulation Compared to Oral Everolimus

Oncotelic Therapeutics, Inc. (OTCQB: OTLC), which holds a 45% ownership stake in the Sapu Nano joint venture, has released new pharmacokinetic and tissue-distribution data demonstrating significant advantages of its intravenous Sapu003 formulation over traditional oral everolimus administration. The data reveals that Sapu003, which utilizes the company's proprietary Deciparticle technology, reduces gastrointestinal drug accumulation by up to 67-fold compared to oral everolimus.

The research findings show that oral everolimus dosing results in extreme gastrointestinal exposure, with drug levels in the stomach reaching up to 2,448 times plasma concentrations. In contrast, intravenous administration of Sapu003 limits gastrointestinal tissue levels to just 36-48 times plasma concentrations. This substantial reduction represents a potential breakthrough in improving patient tolerability while maintaining the drug's intrinsic metabolic profile and providing more consistent systemic exposure.

Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on developing oncology and immunotherapy products to address high-unmet-need cancers and rare pediatric indications. The company's CEO, Dr. Vuong Trieu, has filed more than 150 patent applications and holds 39 issued U.S. patents, contributing to the company's robust intellectual property portfolio. Beyond its internal development programs, Oncotelic participates in joint ventures like GMP Bio, where it maintains a 45% ownership stake under Dr. Trieu's leadership.

The implications of this development extend beyond immediate patient benefits. Reduced gastrointestinal exposure could potentially decrease side effects commonly associated with everolimus treatment, improving patient compliance and quality of life during cancer therapy. For the pharmaceutical industry, this represents progress in drug delivery technology that could be applied to other therapeutic agents with similar gastrointestinal accumulation issues.

The company's news and updates are available through its dedicated newsroom at https://ibn.fm/OTLC. The full press release containing these findings can be accessed at https://ibn.fm/dVPuX. This announcement was distributed through BioMedWire, a specialized communications platform focused on biotechnology and biomedical sciences that operates within the Dynamic Brand Portfolio at IBN, providing comprehensive distribution services across multiple channels including wire solutions, editorial syndication, and social media distribution.

For investors and industry observers, this development represents significant progress in Oncotelic's joint venture portfolio and demonstrates the potential of its Deciparticle technology platform. The reduction in gastrointestinal exposure while maintaining therapeutic efficacy could position Sapu003 as a preferred formulation for everolimus administration, particularly for patients who experience significant gastrointestinal side effects from oral formulations. This advancement aligns with broader trends in oncology drug development that prioritize both efficacy and patient quality of life considerations.